Virothera to present at BIOFUTURE™ 2023 in New York, USA.
‘Next generation immune therapeutic DNA medicines for all.’
Cambridge, UK September 29, 2023 – Virothera, today announced that it is presenting at BioFuture 2023, and also providing an on-demand company presentation. This year, registered in-person attendees to BioFuture can view Virothera’s presentation live, and a recorded version.
Virothera’s CEO Founder, Dr Ursula Gompels, will be presenting Virothera at BioFuture 2023.
The presentation will be on Friday, October 6th, 2023, at 10 am.
Virothera will be introducing our breakthrough proprietary technologies for immune regulation applicable across infectious disease, immune oncology and autoimmune conditions.
CEO Dr Gompels says, “This is an excellent opportunity to present our company, our powerful technologies and our clinical candidates, within one of the main international centres of the biotechnology world. We are honoured to be selected to present at this prestigious event.”
“We are delighted that Virothera will be presenting at BioFuture,” said Sara Demy, CEO of Demy-Colton. “BioFuture brings together today’s very best innovators, investors and business leaders to discuss the forces shaping the future of healthcare, and identify the potential game-changing technologies that will drive the future of drug discovery. We are excited to have Virothera participating in this important event.”
About BioFuture
BioFuture, produced by Demy-Colton, is a conference convening future-focused healthcare thinkers, top investors, stakeholders and cutting-edge companies to “Reimagine the Future of Healthcare”. BioFuture 2023 will be held in-person in New York City on October 4-6, with a virtual access option for digital partnering and recorded content on October 10-12. BioFuture features multiple tracks of plenary sessions, presenting companies, workshops, networking, and an opportunity to schedule one-to-one meetings. BioFuture was founded by Demy-Colton, a leading life sciences and digital health events organization, with a long history of producing high-quality events that build networks between innovative life sciences companies and industry stakeholders. Find out more at https://biofuture.com/
About Virothera
Virothera aims to bring novel gene immune therapeutics to all. Virothera’s technologies regulate protective immunity by new controls to our chemokine system, immune cell conductors recruiting or regulating effective immunity. These are leading to development of novel therapeutics. Its lead candidate is a novel gene based HSV-2 preventative and therapeutic vaccine now approaching the clinic. This is followed by similarly chemokine sensitive targets, an inhibitor of metastatic TN breast cancer and an immune regulator for Rheumatoid Arthritis. Find out more at www.virothera.co.uk
Contacts
Dr Ursula Gompels, CEO – info@virothera.co.uk